FBR & Co reissued their buy rating on shares of AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) in a research note released on Tuesday.

Several other brokerages have also recently commented on AVEO. Piper Jaffray Cos. reiterated a buy rating on shares of AVEO Pharmaceuticals in a research report on Thursday, June 16th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a hold rating to a buy rating and set a $1.00 price target for the company in a research report on Tuesday, May 31st.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 0.8335 on Tuesday. The stock’s 50 day moving average is $0.96 and its 200-day moving average is $0.97. The company’s market cap is $63.23 million. AVEO Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $1.57.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Spark Investment Management LLC purchased a new position in shares of AVEO Pharmaceuticals during the second quarter worth about $281,000. Bridgeway Capital Management Inc. boosted its position in shares of AVEO Pharmaceuticals by 63.7% in the second quarter. Bridgeway Capital Management Inc. now owns 514,051 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 200,000 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of AVEO Pharmaceuticals by 6.0% in the first quarter. Renaissance Technologies LLC now owns 2,094,900 shares of the biopharmaceutical company’s stock worth $1,927,000 after buying an additional 119,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of AVEO Pharmaceuticals by 1.1% in the second quarter. Vanguard Group Inc. now owns 2,470,485 shares of the biopharmaceutical company’s stock worth $2,374,000 after buying an additional 27,304 shares in the last quarter. Finally, New Leaf Venture Partners L.L.C. purchased a new position in shares of AVEO Pharmaceuticals during the second quarter worth about $2,490,000. Hedge funds and other institutional investors own 39.10% of the company’s stock.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

5 Day Chart for NASDAQ:AVEO

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.